Clinical efficacy of pneumococcal conjugate vaccines;Klinische Wirksamkeit von Pneumokokken-Konjugatimpfstoffen

Deutsches Arzteblatt International

Volumn 113, Issue 9, 2016, Pages 93-104

  Ewald, Hannah ^a   Briel, Matthias ^a,b   Vuichard, Danielle ^b   Kreutle, Veronika ^c   Zhydkov, Andriy ^c   Gloy, Viktoria ^a,d  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b MCMASTER UNIVERSITY   (Canada)

^c CANTONAL HOSPITAL AARAU   (Switzerland)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE; VACCINE;

ARTICLE; CLINICAL EFFECTIVENESS; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; CHILD; EPIDEMIOLOGY; FEMALE; GERMANY; HUMAN; INFANT; INTERNATIONAL COOPERATION; MALE; MASS IMMUNIZATION; META ANALYSIS; MIDDLE AGED; MORTALITY; NEWBORN; PNEUMOCOCCAL INFECTIONS; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SEX RATIO; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; TREATMENT OUTCOME; UTILIZATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; GERMANY; HUMANS; INFANT; INFANT, NEWBORN; INTERNATIONALITY; MALE; MASS VACCINATION; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SEX DISTRIBUTION; SURVIVAL RATE; TREATMENT OUTCOME; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 84960850393     PISSN: 18660452     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2016.0139     Document Type: Article

References (54)

1. World Health Organization: Pneumococcal disease www.who.int/ith/diseases/pneu mococcal/en/(last accessed on 16 April 2015).
2. World Health Organization: Pneumococcal conjugate vaccine for childhood immunization-WHO position paper. Releve epidemiologique hebdomadaire/Section d'hygiene du Secretariat de la Societe des Nations = Weekly epidemiological record/Health Section of the Secretariat of the League of Nations 2007; 82: 93-104.
3. O'Brien KL, Wolfson LJ, Watt JP, et al.: Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009; 374: 893-902.
4. World Health Organization, UNICEF, World Bank: State of the world's vaccines and immunization. Geneva: World Health Organization 2009.
5. Frenck RW, Yeh S: The development of 13-valent pneumococcal conjugate vaccine and its possible use in adults. Expert Opin Biol Ther 2012; 12: 63-77.
6. Lucero MG, Dulalia VE, Parreno RN, et al.: Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on x-ray in children under two years of age. Cochrane Database Syst Rev 2004: CD004977.
7. Lucero MG, Dulalia VE, Parreno RN, et al.: Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on x-ray in children under two years of age. Cochrane Database Syst Rev 2004: CD004977.
8. Pavia M, Bianco A, Nobile CG, Marinelli P, Angelillo IF: Efficacy of pneumococcal vaccination in children younger than 24 months: a meta-analysis. Pediatrics 2009; 123: e1103-10.
9. Davies EG, Riddington C, Lottenberg R, Dower N: Pneumococcal vaccines for sickle cell disease. Cochrane Database Syst Rev 2004: CD003885.
10. Davies EG, Riddington C, Lottenberg R, Dower N: Pneumococcal vaccines for sickle cell disease. Cochrane Database Syst Rev 2004: CD003885.
11. Chang CC, Singleton RJ, Morris PS, Chang AB: Pneumococcal vaccines for children and adults with bronchiectasis. Cochrane Database Syst Rev 2009: CD006316.
12. Chang CC, Singleton RJ, Morris PS, Chang AB: Pneumococcal vaccines for children and adults with bronchiectasis. Cochrane Database Syst Rev 2009: CD006316.
13. Fortanier AC, Venekamp RP, Boonacker CW, et al.: Pneumococcal conjugate vac - cines for preventing otitis media. Cochrane Database Syst Rev 2014; 4: CD001480.
14. Conklin L, Loo JD, Kirk J, et al.: Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type Invasive pneumococcal di sease among young children. Pediatr Infect Dis J 2014; 33: 109-18.
15. Loo JD, Conklin L, Fleming-Dutra KE, et al.: Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on prevention of pneumonia. Pediatr Infect Dis J 2014; 33: 140-51.
16. Schönberger K, Kirchgässner K, Riedel C, von Kries R: Effectiveness of 2+ 1 PCV7 vaccination schedules in children under 2 years: A meta-analysis of impact studies. Vaccine 2013; 31: 5948-52.
17. Chevallier B, Vesikari T, Brzostek J, et al.: Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines. Pediatr Infect Dis 2009; 28: 109-18.
18. Oosterhuis-Kafeja F, Beutels P, Van Damme P: Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006). Vaccine 2007; 25: 2194-212.
19. Thompson A, Gurtman A, Patterson S, et al.: Safety of 13-valent pneumococcal conjugate vaccine in infants and children: meta-analysis of 13 clinical trials in 9 countries. Vaccine 2013; 31: 5289-95.
20. Wise RP, Iskander J, Pratt RD, et al.: Postlicensure safety surveillance for 7-valent pneumococcal conjugate vaccine. JAMA 2004; 292: 1702-10.
21. World Health Organization: Pneumococcal vaccines WHO position paper 2012. Wkly Epidemio Rec 2012; 87: 129-44.
22. Ewald H, Gloy V, Briehl M, et al.: Pneumococcal conjugate vaccines for preventing infectious diseases and mortality: protocol for a systematic review of randomised controlled trials. PROSPERO 2014: CRD42014009005 www.crd.york.ac.uk/PROS PERO-REBRANDING/display-record.asp?ID=CRD42014009005.
23. Ewald H, Gloy V, Briehl M, et al.: Pneumococcal conjugate vaccines for preventing infectious diseases and mortality: protocol for a systematic review of randomised controlled trials. PROSPERO 2014: CRD42014009005 www.crd.york.ac.uk/PROS PERO-REBRANDING/display-record.asp?ID=CRD42014009005.
24. Higgins J, Green S: Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011.
25. DerSimonian R, Laird N: Meta-analysis in clinical trials. Controlled clinical trials 1986; 7: 177-88.
26. Egger M, Smith GD, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
27. Black SB, Shinefield HR, Ling S, et al.: Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis 2002; 21: 810-5.
28. Nachman S, Kim S, King J, et al.: Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection. Pediatrics 2003; 112: 66-73.
29. O'Brien KL, Moulton LH, Reid R, et al.: Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet 2003; 362: 355-61.
30. Bassler D, Briel M, Montori VM, et al.: Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA 2010; 303: 1180-7.
31. Bonten MJ, Huijts SM, Bolkenbaas M, et al.: Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015; 372: 1114-25.
32. Dransfield MT, Nahm MH, Han MK, et al.: Superior immune response to proteinconjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 499-505.
33. Jackson LA, Gurtman A, Rice K, et al.: Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2013; 31: 3585-93.
34. Jackson LA, Gurtman A, van Cleeff M, et al.: Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 2013; 31: 3577-84.
35. Macintyre CR, Ridda I, Gao Z, et al.: A randomized clinical trial of the immunogenicity of 7-valent pneumococcal conjugate vaccine compared to 23-valent polysaccharide vaccine in frail, hospitalized elderly. PLoS One 2014; 9: e94578.
36. Hammitt LL, Ojal J, Bashraheil M, et al.: Immunogenicity, impact on carriage and reactogenicity of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Kenyan children aged 1-4 years: a randomized controlled trial. PLoS One 2014; 9: e85459.
37. Pomat WS, van den Biggelaar AH, Phuanukoonnon S, et al.: Safety and immunogenicity of neonatal pneumococcal conjugate vaccination in Papua New Guinean children: a randomised controlled trial. PLoS One 2013; 8: e56698.
38. Palmu AA, Jokinen J, Borys D, et al.: Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet 2013; 381: 214-22.
39. Black S, Shinefield H, Fireman B, et al.: Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19: 187-95.
40. Klugman KP, Madhi SA, Huebner RE, et al.: A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003; 349: 1341-8.
41. Drijkoningen JJ, Rohde GG: Pneumococcal infection in adults: burden of disease. Clin Microbiol Infec 2014; 20: 45-51.
42. Barten G, Schutte H, Bals R, Pletz M, Rohde G: [Symposium: Pneumonia 2010-state of the art]. Pneumologie (Stuttgart, Germany) 2011; 65: 223-8.
43. Robert Koch-Institut: Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut: Begründungen zur allgemeinen Empfehlung der Impfungen gegen Pneumokokken und Meningokokken im Säuglings- und Kindesalter. Epidemiologisches Bulletin 2006; 31: 255-70.
44. van der Linden M, Weiß S, Falkenhorst G, Siedler A, Imöhl M, von Kries R: Four years of universal pneumococcal conjugate infant vaccination in Germany: Impact on incidence of invasive pneumococcal disease and serotype distribution in children. Vaccine 2012; 30: 5880-5.
45. Liese JG, Silfverdal SA, Giaquinto C, et al.: Incidence and clinical presentation of acute otitis media in children aged < 6 years in European medical practices. Epidemiol Infect 2014; 142: 1778-88.
46. Hausdorff WP, Bryant J, Paradiso PR, Siber GR: Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clinical infec - tious diseases: An official publication of the Infectious Diseases Society of America 2000; 30: 100-21.
47. Madhi SA, Petersen K, Madhi A, Wasas A, Klugman KP: Impact of human immunodeficiency virus type 1 on the disease spectrum of Streptococcus pneumoniae in South African children. Pediatr Infect Dis J 2000; 19: 1141-7.
48. European Centre for Disease Prevention and Control: Annual Epidemiological Report 2013. Reporting on 2011 surveillance data and 2012 epidemic intelligence data. Stockholm: ECDC 2013.
49. Pilishvili T, Lexau C, Farley MM, et al.: Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201: 32-41.
50. Davis S, Feikin D, Johnson HL: The effect of Haemophilus influenzae type B and pneumococcal conjugate vaccines on childhood meningitis mortality: a systematic review. BMC Public Health 2013; 13 (Suppl 3): S21.
51. Taylor S, Marchisio P, Vergison A, Harriague J, Hausdorff WP, Haggard M: Impact of pneumococcal conjugate vaccination on otitis media: a systematic review. Clin Infect Dis 2012; 54: 1765-73.
52. Deloria Knoll M, Park DE, Johnson TS, et al.: Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on immunogenicity. Pediatr Infect Dis J 2014; 33: 119-29.
53. Fleming-Dutra KE, Conklin L, Loo JD, et al.: Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type nasopharyngeal carriage. Pediatr Infect Dis J 2014; 33: 152-60.
54. Loo JD, Conklin L, Fleming-Dutra KE, et al.: Systematic review of the indirect effect of pneumococcal conjugate vaccine dosing schedules on pneumococcal disease and colonization. Pediatr Infect Dis J 2014; 33: 161-71.
55. O'Brien KL, Goldblatt D, Whitney CG: Why Do we need a systematic review of pneumococcal conjugate vaccine dosing schedules? Pediatr Infect Dis J 2014; 33: 107-8.
56. Park DE, Johnson TS, Nonyane BAS, et al.: The differential impact of coadministered vaccines, geographic region, vaccine product and other covariates on pneumococcal conjugate vaccine Immunogenicity. Pediatr Infect Dis J 2014; 33: 130-9.
57. Whitney CG, Goldblatt D, O'Brien KL: Dosing schedules for pneumococcal conjugate vaccine: Considerations for policy makers. Pediatr Infect Dis J 2014; 33: 172-81.
58. Moberley S, Holden J, Tatham DP, Andrews RM: Vaccines for preventing pneumococcal infection in adults. Cochrane database Syst Rev 2013; 1: CD000422.